Vision In Preschoolers Study (VIP Study)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00038753|
Recruitment Status : Unknown
Verified October 2009 by National Eye Institute (NEI).
Recruitment status was: Active, not recruiting
First Posted : June 5, 2002
Last Update Posted : October 16, 2009
|Condition or disease||Intervention/treatment||Phase|
|Amblyopia Strabismus Refractive Error||Procedure: Vision Screening||Phase 3|
The Vision In Preschoolers (VIP) Study is a multi-center, multidisciplinary, prospective clinical study to evaluate screening tests for identifying preschool children in need of comprehensive eye examinations. The primary goal of the VIP Study is to identify an effective and efficient battery of screening tests that has high sensitivity and specificity in identifying preschoolers in need of further evaluation for amblyopia, strabismus and/or significant refractive error.
The VIP Study is designed in three-phases.
Phase I activities will establish which screening tests perform well when administered by licensed eye care professionals (pediatric optometrists and pediatric ophthalmologists) in a population of 1000 Head Start preschoolers at high risk for the targeted vision disorders.
Phase II activities will provide evaluation of the tests' performance when administered by pediatric nurses and lay people on a high risk population of 1000 Head Start preschoolers. Each child will be tested twice with each screening test - once by a pediatric nurse and once by a lay screener. Tests selected for Phase II will be determined by the outcome of Phase I.
Phase III activities will evaluate the performance of the tests in identifying individuals with specific vision disorders in a general population of (6400) Head Start preschoolers. The category of screening personnel and the specific screening tests used in Phase III will be determined by the outcome of Phases I and II.
|Study Type :||Interventional (Clinical Trial)|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00038753
|United States, California|
|University of California, Berkeley School of Optometry|
|Berkeley, California, United States, 94720-2020|
|United States, Massachusetts|
|New England College of Optometry|
|Boston, Massachusetts, United States, 02215|
|United States, Ohio|
|The Ohio State University College of Optometry|
|Columbus, Ohio, United States, 43218-2342|
|United States, Oklahoma|
|Oklahoma Northeastern State University College of Optometry|
|Tahlequah, Oklahoma, United States, 74464|
|United States, Pennsylvania|
|Pennsylvania College of Optometry|
|Philadelphia, Pennsylvania, United States, 19141|